We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

Guggenheim initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $45 price target The firm has a positive view of NBD1 ...

With accurate diagnosis, personalised treatment, and proper medical guidance, many men with genetic infertility can achieve fatherhood and experience the joy of parenthood., Health News - Times Now ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of ...

Researchers from the Organoid group at the Hubrecht Institute have found that specific gut cells, BEST4/CA7+ cells, regulate electrolyte and water ...

A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will be ...

Objective: Intestinal current measurement (ICM) provides a sensitive bioassay for assessment of cystic fibrosis transmembrane conductance regulator (CFTR) function in rectal biopsies ex vivo and is ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced the Phase I/II LENTICLAIR 1 trial of inhaled lentiviral vector-based gene ...

I am equally pleased to announce that Duncan McKechnie ... The U.S. launch is underway for ALYFTREK, the fifth Vertex CFTR modulator regimen, while we are also working to secure approval in ...

Sionna is developing therapies that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein as a treatment for CF patients. The company is currently ...